

News Releases

All Years

Search

Go

[Advanced Search](#)

- JUL 16, 2026

Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to \$500.0 Million
- JUN 15, 2026

Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma
- MAY 14, 2026

Inhibrx Reports First Quarter 2026 Financial Results
- MAY 11, 2026

Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy
- MAY 8, 2026

Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC

Show 5 per page

